Your browser doesn't support javascript.
loading
Combination of PARP Inhibitor Olaparib, and PD-L1 Inhibitor Durvalumab, in Recurrent Ovarian Cancer: a Proof-of-Concept Phase II Study.
Lampert, Erika J; Zimmer, Alexandra; Padget, Michelle; Cimino-Mathews, Ashley; Nair, Jayakumar R; Liu, Yingmiao; Swisher, Elizabeth M; Hodge, James W; Nixon, Andrew B; Nichols, Erin; Bagheri, Mohammad H; Levy, Elliott; Radke, Marc R; Lipkowitz, Stanley; Annunziata, Christina M; Taube, Janis M; Steinberg, Seth M; Lee, Jung-Min.
Afiliación
  • Lampert EJ; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Zimmer A; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Padget M; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Cimino-Mathews A; Department of Pathology, The Johns Hopkins Medical Institution, Baltimore, Maryland.
  • Nair JR; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Liu Y; Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Swisher EM; Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, University of Washington, Seattle, Washington.
  • Hodge JW; Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Nixon AB; Department of Medicine, Duke University Medical Center, Durham, North Carolina.
  • Nichols E; Clinical Research Directorate, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, Bethesda, Maryland.
  • Bagheri MH; Department of Radiology and Imaging Sciences, Clinical Center, National Cancer Institute, Bethesda, Maryland.
  • Levy E; Interventional Radiology, NIH Clinical Center, Bethesda, Maryland.
  • Radke MR; Division of Gynecologic Oncology, Departments of Obstetrics and Gynecology, University of Washington, Seattle, Washington.
  • Lipkowitz S; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Annunziata CM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Taube JM; Department of Dermatopathology, The Johns Hopkins Medical Institution, Baltimore, Maryland.
  • Steinberg SM; Biostatistics and Data Management Section, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
  • Lee JM; Women's Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland. leej6@mail.nih.gov.
Clin Cancer Res ; 26(16): 4268-4279, 2020 08 15.
Article en En | MEDLINE | ID: mdl-32398324
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Poli(ADP-Ribosa) Polimerasas / Antígeno B7-H1 / Anticuerpos Monoclonales Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Ftalazinas / Piperazinas / Poli(ADP-Ribosa) Polimerasas / Antígeno B7-H1 / Anticuerpos Monoclonales Límite: Adult / Aged / Aged80 / Female / Humans / Middle aged Idioma: En Revista: Clin Cancer Res Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article